ATE464903T1 - Analgetische zusammensetzung enthaltend ein opioid und einen natriumkanalblocker - Google Patents

Analgetische zusammensetzung enthaltend ein opioid und einen natriumkanalblocker

Info

Publication number
ATE464903T1
ATE464903T1 AT02734980T AT02734980T ATE464903T1 AT E464903 T1 ATE464903 T1 AT E464903T1 AT 02734980 T AT02734980 T AT 02734980T AT 02734980 T AT02734980 T AT 02734980T AT E464903 T1 ATE464903 T1 AT E464903T1
Authority
AT
Austria
Prior art keywords
sodium channel
opioid
composition containing
channel blocker
analgesic composition
Prior art date
Application number
AT02734980T
Other languages
German (de)
English (en)
Inventor
Baoshan Ku
Frank Shum
Original Assignee
Wex Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wex Medical Ltd filed Critical Wex Medical Ltd
Application granted granted Critical
Publication of ATE464903T1 publication Critical patent/ATE464903T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02734980T 2001-05-18 2002-05-20 Analgetische zusammensetzung enthaltend ein opioid und einen natriumkanalblocker ATE464903T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB011180986A CN1269482C (zh) 2001-05-18 2001-05-18 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
PCT/CN2002/000339 WO2002094272A1 (en) 2001-05-18 2002-05-20 Analgesic composition and method

Publications (1)

Publication Number Publication Date
ATE464903T1 true ATE464903T1 (de) 2010-05-15

Family

ID=4662967

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02734980T ATE464903T1 (de) 2001-05-18 2002-05-20 Analgetische zusammensetzung enthaltend ein opioid und einen natriumkanalblocker

Country Status (9)

Country Link
US (2) US6780866B2 (https=)
EP (1) EP1387685B1 (https=)
JP (1) JP2004529959A (https=)
CN (1) CN1269482C (https=)
AT (1) ATE464903T1 (https=)
CA (1) CA2485337C (https=)
DE (1) DE60236077D1 (https=)
ES (1) ES2344631T3 (https=)
WO (1) WO2002094272A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284536C (zh) * 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
MXPA04004543A (es) 2001-11-15 2005-03-31 Micro Algae Corp Composiciones farmaceuticas que contienen 3,4-propinoperhidropurinas y sus usos para el bloqueo de la transmision neuronal.
CN1568999A (zh) 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
JP2007538010A (ja) * 2004-05-07 2007-12-27 ファイトトックス リミテッド フィコトキシンの経皮投与
JP2007536269A (ja) * 2004-05-07 2007-12-13 ファイトトックス リミテッド ゴニオトキシンを用いた創傷の治療方法
CN101039675A (zh) * 2004-09-22 2007-09-19 埃斯蒂文博士实验室股份有限公司 河豚毒素及其衍生物用于治疗外周神经源性神经痛
EP1702627A1 (en) * 2005-03-18 2006-09-20 Laboratorios Del Dr. Esteve, S.A. Analgesic combination of sodium channel blockers with opioid antagonists
US20100048592A1 (en) * 2005-08-25 2010-02-25 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the management of musculoskeletal pain
WO2007025212A2 (en) * 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
ES2691411T3 (es) 2006-03-27 2018-11-27 Wex Medical Limited Uso de bloqueadores de los canales de sodio para el tratamiento del dolor neuropático que se desarrolla como consecuencia de la quimioterapia

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022899A (en) 1973-06-12 1977-05-10 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4906779A (en) * 1986-07-10 1990-03-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US5262568A (en) * 1990-03-02 1993-11-16 State Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
WO1993013128A1 (en) * 1991-12-30 1993-07-08 Neurex Corporation Methods of producing analgesia and enhancing opiate analgesia
NZ268969A (en) 1993-07-23 1997-06-24 Toray Industries Morphinan derivatives and pharmaceutical compositions
WO1995023132A1 (en) * 1994-02-23 1995-08-31 Cambridge Neuroscience, Inc. Blockers of ion channels and methods of use thereof
AU1888195A (en) * 1994-03-17 1995-10-03 Nanning Maple Leaf Pharmaceutical Co. Ltd. The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence
GB9513180D0 (en) * 1995-06-28 1995-08-30 Univ London Ion channel
DE19602970A1 (de) 1995-12-20 1997-07-31 Nycomed Arzneimittel Gmbh Neue 7,8- Dihydromorphinderivate, Verfahren zu deren Herstellung und deren Verwendung
CN1072486C (zh) * 1996-09-24 2001-10-10 王维国 用于戒毒、镇痛的药剂及其制法
CN1081034C (zh) * 1997-03-07 2002-03-20 潘心富 一种双胍基氢化嘌呤环类化合物的戒毒药
WO1998043619A2 (en) * 1997-04-02 1998-10-08 The Regents Of The University Of California Method of local anesthesia
AU7389098A (en) * 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
DE19936719A1 (de) * 1999-08-06 2001-02-15 Gruenenthal Gmbh Substituierte 1,5-Dihydropyrrol-2-on-Derivate
CN1284536C (zh) 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
CN1203857C (zh) * 2000-09-18 2005-06-01 威克斯医药有限公司 局部麻醉与镇痛的新方法
CN1236773C (zh) * 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用

Also Published As

Publication number Publication date
US20040214842A1 (en) 2004-10-28
CN1386505A (zh) 2002-12-25
DE60236077D1 (de) 2010-06-02
JP2004529959A (ja) 2004-09-30
EP1387685A1 (en) 2004-02-11
EP1387685B1 (en) 2010-04-21
CN1269482C (zh) 2006-08-16
US6780866B2 (en) 2004-08-24
US20020198226A1 (en) 2002-12-26
CA2485337C (en) 2007-08-28
WO2002094272A1 (en) 2002-11-28
ES2344631T3 (es) 2010-09-02
CA2485337A1 (en) 2002-11-28
EP1387685A4 (en) 2007-05-23

Similar Documents

Publication Publication Date Title
EE200300106A (et) Farmatseutiline kompositsioon kui süsteemne analgeetikum
BR0316027A (pt) Formulações de toxina botulina para administração oral
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
ATE464903T1 (de) Analgetische zusammensetzung enthaltend ein opioid und einen natriumkanalblocker
UA83659C2 (ru) Антагонисты рецепторов p2x7 и их применение, фармацевтическая композиция на их основе, способ их получения (варианты)
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
EA200600696A1 (ru) Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
UA89615C2 (ru) Фармацевтические композиции, которые содержат никотиновую кислоту и антагонист рецептора dp
IL136591A (en) Nasal pharmaceutical solutions
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
MXPA03010761A (es) Combinaciones farmaceuticas.
MXPA03007885A (es) Norbuprenorfina n-but-3-enilo y metodos de uso.
BRPI0413676A (pt) composto, e, composição farmacêutica
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
MXPA03005980A (es) Composiciones para administracion nasal de insulina.
BG108452A (en) Tablet comprising cetirizine and pseudoephedrine
NO20051023L (no) Oral administrering av calcitonin
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
CA2493885A1 (en) Use of sodium channel blocking compounds and aspirin in manufacturing drugs for producing synergistically analgesic effect in mammals
EA200501565A1 (ru) Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса
MA31227B1 (fr) Composition pharmaceutique renfermant du phloroglucinol et du paracetamol.
TW200510371A (en) Novel formulations for opioid-based treatments of pain comprising 1-(1, 2-disubstituted piperidinyl)-4-substituted piperazine derivatives
DK1420789T3 (da) Anvendelse af aktivstoffer med my-opioid-receptoragonistisk virkning og opioid-receptorantagonistisk virkning som kombinationslægemidler til cancerbehandling
SE0203817D0 (sv) New composition

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties